Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs

Journal of the American College of Cardiology

Volumn 32, Issue 6, 1998, Pages 1787-1796

  Jalowy, Andreas ^a   Schulz, Rainer ^a   Dörge, Hilmar ^a   Behrends, Matthias ^a   Heusch, Gerd ^a,b  

^a Zentrum fur Innere Medizin   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CANDESARTAN; ICATIBANT; INDOMETACIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMODYNAMICS; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SWINE;

ANIMALS; BENZIMIDAZOLES; BRADYKININ; CYCLOOXYGENASE INHIBITORS; DRUG COMBINATIONS; FEMALE; IMIDAZOLES; INDOMETHACIN; MALE; MYOCARDIAL INFARCTION; PROSTAGLANDINS; PYRIDINES; RECEPTORS, ANGIOTENSIN; RECEPTORS, BRADYKININ; SIGNAL TRANSDUCTION; SWINE; SWINE, MINIATURE; TETRAZOLES;

EID: 0032533590     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00441-0     Document Type: Article

References (60)

1. Helin K, Stoll M, Meffert S, Stroth U, Unger T. The role of angiotensin receptors in cardiovascular disease. Ann Med 1997;29:23-29.
2. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993;27:334-40.
3. Kitakaze M, Minamino T, Node K, et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 1995;92:950-61.
4. Werrmann JG, Cohen SM. Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol 1994;24:573-86.
5. Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994;128:1-6.
6. Kohya T, Yokoshiki H, Tohse N, et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: beneficial effect of angiotensin II blockade. Circ Res 1995;76:892-9.
7. Wiemer G, Schölkens BA, Busse R, Wagner A, Heitsch H, Linz W. The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 1993;3:24-7.
8. Thomas GP, Ferrier GR, Howlett SE. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther 1996;278: 1090-7.
9. Liu Y-H, Yang X-P, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-35.
10. Schwarz ER, Montino H, Fleischhauer J, Klues HG, vom Dahl J, Hanrath P. Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther 1997;11:687-95.
11. Liu Y-H, Yang X-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996;27:7-13.
12. 1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 1996;31:568-76.
13. Staub HM, Zhu Y-C, Redlich T, et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk 1994;1:255-62.
14. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993;234:229-36.
15. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995;27:883-92.
16. 1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 1997;29:129-39.
17. Richard V, Ghaleh B, Berdeaux A, Giudicelli J-F. Comparison of the effects of EXP3174, an angiotensin II antagonist, and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 1993;110:969-74.
18. Weaver ME, Pantely GA, Bristow JD, Ladley HD. A quantitative study of the anatomy and distribution of coronary arteries in swine in comparison with other animals and man. Cardiovasc Res 1986;20:907-17.
19. White FC, Bloor CM. Coronary collateral circulation in the pig: correlation of collateral flow with coronary bed size. Basic Res Cardiol 1981;76:189-96.
20. Schaper W, Görge G, Winkler B, Schaper J. The collateral circulation of the heart. Prog Cardiovasc Dis 1988;31:57-77.
21. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997;11 Suppl 2:S19-25.
22. Seyedi N, Xu XB, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.
23. Blankley CJ, Hodges JC, Klutcho SR, et al. Synthesis and structure-activity relationship of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem 1991;34:3248-60.
24. Wirth K, Hock FJ, Albus U, et al. HOE 140 a new potent and long-acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991;102:774-7.
25. Ehring T, Baumgart D, Krajcar M, Hümmelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE-inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins, but not nitric oxide. Circulation 1994;90:1368-85.
26. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
27. Schulz R, Guth BD, Heusch G. No effect of coronary perfusion on regional myocardial function within the autoregulatory range in pigs: evidence against the Gregg phenomenon. Circulation 1991;83:1390-1403.
28. Schulz R, Miyazaki S, Miller M, et al. Consequences of regional inotropic stimulation of ischemic myocardium on regional myocardial blood flow and function in anesthetized swine. Circ Res 1989;64:1116-26.
29. Schulz R, Post H, Sakka S, Wallbridge DR, Heusch G. Intraischemic preconditioning: increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia without intermittent reperfusion. Circ Res 1995;76:942-50.
30. Keiser JA, Bjork FA, Hodges JC, Taylor DG. Renal hemodynamic and excretory responses to PD123319 and losartan, nonpeptide AT1 and AT2 subtype-specific angiotensin II ligands. J Pharmacol Exp Ther 1992;262: 1154-60.
31. Schulz R, Post H, Vahlhaus C, Heusch G. Ischemic preconditioning in pigs: a graded phenomenon. Its relation to adenosine and bradykinin. Circulation 1998;98:1022-9.
32. Skyschally A, Schulz R, Heusch G. Cordat II: a new program for data acquisition and on-line calculation of hemodynamic and regional myocardial dimension parameters. Comput Biol Med 1993;23:359-67.
33. Klein HH, Puschmann S, Schaper J, Schaper W. The mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. Virchows Arch 1981;393:287-97.
34. Go LO, Murry CE, Richard VJ, Weischedel GR, Jennings RB, Reimer KA. Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury. Am J Physiol 1988;255:H1188-98.
35. Hill JL, Gettes LS. Effect of acute coronary artery occlusion on local myocardial extracellular K+ activity in swine. Circulation 1980;61:768-78.
36. Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990;66:1133-42.
37. Vanoverschelde J-LJ, Wijns W, Depré C, et al. Mechanisms of chronic regional postischemic dysfunction in humans: new insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-23.
38. Nienaber CH, Gottwik M, Winkler B, Schaper W. The relationship between the perfusion deficit, infarct size and time after experimental coronary artery occlusion. Basic Res Cardiol 1983;78:210-26.
39. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new angiotensin II receptor antagonist candesartan cilexitil in rats and dogs. Drug Res 1996;46:594-600.
40. Takeda K, Fujita H, Nakamura K, et al. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press 1994;3 Suppl 5:94-8.
41. Farsang C, Kórház SI, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination [abstract]. Am J Hypertens 1997;10:80A.
42. Ito K, Shiomi M, Kito G. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 1995;18:69-75.
43. de Carvalho Frimm C, Sun Y, Weber KT. Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 1997;129: 439-46.
44. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes. J Clin Invest 1995; 95:46-54.
45. Stoll M, Steckelings UM, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7.
46. Spinale FG, de Gasparo M, Whitebread S, et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I: effects on left ventricular performance and neurohormonal systems. Circulation 1997;96:2385-96.
47. Asano K, Dutcher DL, Port D, et al. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 1997;95:1193-1200.
48. 2-receptors in the normal and failing human heart. J Pharmacol Exp Ther 1998;284:323-36.
49. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-8.
50. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988;84 Suppl 3A:61-6.
51. 2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996;94: 3087-9.
52. Zhang J, Pfaffendorf M, van Zwieten PA. Effect of various angiotensin receptor antagonism on cardiovascular responses to angiotensin II in pithed rats. J Cardiovasc Pharmacol 1994;24:108-13.
53. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
54. Jaiswal N, Diz DI, Tallant EA, Khosla MC, Ferrario CM. The nonpeptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens 1991;4:228-33.
55. Hohlfeld T, Strobach H, Schrör K. Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury. J Pharmacol Exp Ther 1993;264:397-405.
56. Hohlfeld T, Strobach H, Schrör K. Stimulation of prostacyclin synthesis by defibrotide: improved contractile recovery from myocardial "stunning." J Cardiovasc Pharmacol 1991;17:108-15.
57. Rutherford JD, Pfeffer MA, Mojé LA, et al. Effects of captopril on ischemic events after myocardial infarction: results of the survival and ventricular enlargement trial. Circulation 1994;90:1731-8.
58. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-85.
59. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
60. Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995;92:825-34.